Form 4: Corcept Therapeutics Director Exercises Options and Sells Shares

A Corcept Therapeutics director, Daniel N. Swisher Jr., exercised stock options and sold shares on November 11, 2024, according to a recent SEC filing.

Summary

• On November 11, 2024, Daniel N. Swisher Jr., a director at Corcept Therapeutics, exercised stock options to acquire 2,200 shares of common stock at a price of $12.13 per share.
• Simultaneously, Mr. Swisher sold 2,200 shares of common stock at a price of $59.88 per share.
• These transactions were executed under a pre-arranged 10b5-1 trading plan.
• Following these transactions, Mr. Swisher directly owns 0 shares of common stock.
• Mr. Swisher also holds options for 12,800 shares of common stock, which are fully exercisable.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity, which is neither positive nor negative in itself. The transactions were pre-planned and do not indicate any change in the company's outlook.

Industry Context

This is a routine filing related to insider trading activity. It is common for directors and officers to exercise stock options and sell shares, often under pre-arranged trading plans.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate insiders to avoid accusations of insider trading.
• The reported transactions are typical for directors who receive stock options as part of their compensation.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine and pre-planned.

Key Dates

Keywords

Corcept Therapeutics, insider trading, stock options, SEC Form 4, Daniel N. Swisher Jr., 10b5-1 plan, share sale, director